Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study
R P Collea, F W Kruter, J E Cantrell, T K George, S Kruger, A M Favret, D L Lindquist, A M Melnyk, R E Pluenneke, S H Shao, M W Crockett, L Asmar, J O'Shaughnessy, R P Collea, F W Kruter, J E Cantrell, T K George, S Kruger, A M Favret, D L Lindquist, A M Melnyk, R E Pluenneke, S H Shao, M W Crockett, L Asmar, J O'Shaughnessy
Abstract
Background: We determined the objective response rates produced by pegylated liposomal doxorubicin (PLD) plus carboplatin with/without trastuzumab (Herceptin).
Patients and methods: Patients with measurable disease were stratified by taxane treatment history and human epidermal growth factor receptor-2 status.
Treatment: PLD 30 mg/m(2) followed by carboplatin, day 1 of each 28-day cycle; human epidermal growth factor receptor-2 (HER2)-positive patients also received trastuzumab.
Results: Arm 1 received PLD plus carboplatin (N = 41 arm 1a, taxane naive; N = 42 arm 1b, taxane pretreated); Arm 2 patients received PLD plus carboplatin + Herceptin (N = 46). Overall response rates: 31%, 31%, and 56%, respectively. Median overall survival durations were not reached in arm 1a and were 13 and 33 months for arms 1b and 2. Median progression-free survival: 8, 5, 10 months, respectively. Grades 3-4 treatment-related toxic effects for arms 1a, 1b, 2, respectively, were neutropenia 22%, 31%, 35%; thrombocytopenia 34%, 26%, 17%; and fatigue 2%, 14%, 13%.
Conclusions: PLD plus carboplatin has moderate antitumor activity and excellent tolerability. Herceptin and PLD plus carboplatin in HER2-positive patients have antitumor activity without significant cardiac toxicity. Toxicity results suggest that PLD can be combined with Herceptin with minimal cardiac toxicity.
Trial registration: ClinicalTrials.gov NCT00303108.
Source: PubMed